Ceretype Neuromedicine

About:

Ceretype Neuromedicine is a next-generation fMRI brain biomarker platform to improve drug discovery and patient care in neuropsychiatry

Website: http://ceretype.com/

Top Investors: THE CATALYTIC IMPACT FOUNDATION (CIF), One Mind Accelerator, Leafy Tunnel, WPSS.bio, Cedar Street Group

Description:

Ceretype has pioneered the integration of fMRI into therapeutic applications in neuropsychiatry. Our uniquely scalable platform makes targeted biomarkers accessible, delivering actionable insights for our pharma/biotech partners. Our decades of expertise across neuromedicine, brain imaging, and industry processes enables innovations that will ultimately transform patient care.

Total Funding Amount:

$4.35M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)ceretype.com

Founders:

David Silbersweig, Emily Stern, Hong Pan

Number of Employees:

11-50

Last Funding Date:

2024-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai